Market Overview

Vetr Upgrades Merrimack Following Earnings, Licensing Rumors


The Vetr crowd upgraded their rating for Merrimack Pharmaceuticals Inc (NASDAQ: MACK) from the previous rating of 2 stars (Sell), issued 20 days ago, to 5 stars (Strong Buy). Sentiment in the stock among the crowd is still middling, with 57 percent of Vetr user ratings bullish.

Interest in Merrimack jumped earlier this month upon rumors that the company was working with investment banks on the possibility of licensing its cancer treatment drug to larger biopharmaceutical companies. Shares of Merrimack traded recently around $6.03, about 10.7 percent lower from where it was at its post-rumor high of $6.75 on November 14.

See how crowdsourced ratings could help you time the markets.

The crowd's target price for Merrimack is at $10.86, which is just below the average analyst target price of $11.00. Less than 2 percent of Vetr users are holding MACK in their watch lists.

Latest Ratings for MACK

Oct 2018MaintainsNeutralNeutral
Jun 2018MaintainsNeutralNeutral
Jun 2018DowngradesNeutralUnderweight

View More Analyst Ratings for MACK
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Rumors Crowdsourcing Analyst Ratings General


Related Articles (MACK)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

OPEC Meeting Sparks Vetr's Interest In Marathon Oil

ArcView CEO Troy Dayton Shares Optimistic Outlook For The Marijuana Industry Under Trump